Physician profile
Aneel Akbar Chowdhary
NPI 1447451067
$420,040.65
in general payments reported to CMS, 2019-2025
25 companies · $54K in 2025
The $54K reported for 2025 was more than what 95% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $17K · 2021: $54K · 2022: $68K · 2023: $90K · 2024: $66K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $137K · Consulting Fee: $35K · Travel and Lodging: $30K · Food and Beverage: $5,084 · Honoraria: $2,750 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,223.50 |
| Consulting Fee | $34,552.50 |
| Travel and Lodging | $29,579.40 |
| Food and Beverage | $5,083.63 |
| Honoraria | $2,750.00 |
| Education | $108.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $170,511.24 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Merck Sharp & Dohme LLC | $135,931.77 | 2019-2025 | Keytruda |
| Amgen INC. | $41,499.14 | 2019-2025 | Lumakras, Imdelltra (Amg757), Imdelltra (Amg 757) |
| Mirati Therapeutics, INC. | $28,631.83 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $9,182.99 | 2025 | Libtayo |
| Janssen Biotech, INC. | $7,062.87 | 2024-2025 | Rybrevant, Erleada |
| Kite Pharma, INC. | $5,896.53 | 2022-2023 | Yescarta |
| Seagen INC. | $5,830.98 | 2022-2023 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $2,261.10 | 2023-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $2,242.92 | 2023-2025 | |
| Heron Therapeutics, INC. | $1,923.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,785.00 | 2025 | Alunbrig |
| Janssen Scientific Affairs, LLC | $1,579.23 | 2022-2024 | Rybrevant |
| Genentech USA, INC. | $1,515.00 | 2021 | |
| Puma Biotechnology, INC. | $1,000.00 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $852.86 | 2019-2025 | Pemazyre, Zynyz, Jakafi |
| Daiichi Sankyo INC. | $750.00 | 2022-2023 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Celgene Corporation | $368.20 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $252.79 | 2022 | |
| Davol INC. | $170.28 | 2025 | Arista |
| Ipsen Biopharmaceuticals, INC | $108.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $100.86 | 2019 | |
| Sobi, INC | $71.26 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneel Chowdhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.